Dallas, December 13, 2021—What can you do with some 2022 insurance plans no longer covering Eliquis, Pradaxa, and Savaysa? What is the problem? We have become aware that CVS Caremark, the company that manages the prescription medications for many US health insurance plans, has decided to drop coverage for Eliquis, Pradaxa, and Savaysa from many …
Read More
Big news! Boehringer Ingelheim has submitted an application to the FDA requesting accelerated approval for idarucizumab, the reversal agent for Pradaxa (dabigatran). See: Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® Additionally, they have submitted for marketing approval by Health Canada and the European Medicines Agency (EMA). See: Boehringer …
Read More
Good to see the FDA moving on this as we're starting to hear of afib patients with mechanical heart valves getting Pradaxa. Here is the FDA announcement... ISSUE: The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used …
Read More
Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States--dabigatran (Pradaxa®) and rivaroxaban …
Read More
StopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: http://www.stopafib.org/newsitem.cfm/NEWSID/397 Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban …
Read More
StopAfib.org interviews Dr. Elaine Hylek of Boston University. A transcript of this video, as well as additional information about the topics discussed, and Dr. Hylek, can be found at: http://www.stopafib.org/newsitem.cfm/NEWSID/349 In this video interview, Dr. Elaine Hylek of Boston University discusses new anticoagulant drugs for stroke prevention in atrial fibrillation. For many years, warfarin (Coumadin) …
Read More
As a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them. There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits …
Read More
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed …
Read More
The long-awaited alternative to Coumadin (warfarin) has just been approved by the US FDA. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation for preventing afib-related strokes. The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa …
Read More
An FDA panel today unanimously recommended that the FDA approve dabigatran (Pradaxa) for reducing the risk of afib strokes. FDA approval is expected quickly, making this the first alternative to warfarin approved in the United States, and also the first atrial fibrillation approval for dabigatran. It is approved in over 70 countries for venous thromboembolisms …
Read More